Clinical research advances in chimeric antigen receptor T-cell therapy for primary liver cancer
10.3969/j.issn.1001-5256.2023.05.004
- VernacularTitle:嵌合抗原受体T细胞治疗原发性肝癌临床研究进展
- Author:
Shuang LI
1
,
2
;
Zherui LIU
1
,
2
;
Qi ZHAO
1
;
Yinying LU
2
Author Information
1. Peking University 302 Clinical Medical School, Beijing 100039, China
2. Department of Liver Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
- Publication Type:Discussions by Experts
- Keywords:
Receptors, Chimeric Antigen;
T-Lymphocytes;
Carcinoma, Hepatocellular;
Therapeutics
- From:
Journal of Clinical Hepatology
2023;39(5):1019-1029
- CountryChina
- Language:Chinese
-
Abstract:
Primary liver cancer (PLC) has the features of insidious onset and difficulties in early diagnosis, with limited and ineffective therapeutic options. Chimeric antigen receptor (CAR) T-cell therapy is a genetically modified T-cell therapy that recognizes tumor-specific antigens and activates T cells to exert a tumor-killing effect. CAR T-cell therapy has made great progress in the treatment of hematological tumors and has achieved a good clinical effect in the field of solid tumors in recent years, and although CAR T-cell therapy has developed from the first to the fifth generation, there are still many challenges in the field of solid tumors. This article comprehensively reviews the mechanisms of CAR T-cell therapy for PLC and related research advances, including the main targets such as GPC3, AFP, MUC1, and NKG2D in CAR T-cell therapy for PLC, CAR T-cell therapy for PLC and oncolytic virus, and combined treatment with immune checkpoint inhibitors, as well as the advances in the biological, preclinical, and clinical studies on these targets and treatment modalities and the challenges and solutions for CAR T-cell therapy in the treatment of PLC, so as to provide a reference for the future clinical development of CAR T-cell therapy in liver cancer.
